Trial Profile
Prospective study of I-131 3-iodobenzylguanidine radiotherapy for high-risk neuroblastoma; in accordance with the Japanese Advanced Medical Care B program for the anticancer drug with high medical needs
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 29 May 2019
Price :
$35
*
At a glance
- Drugs Iobenguane (Primary) ; Antineoplastics
- Indications Neuroblastoma
- Focus Adverse reactions
- 27 May 2019 Status changed from not yet recruiting to discontinued.
- 16 Dec 2016 New trial record